Category Archives: PLB1003 – Beijing Pearl Biotechnology

Clinical Trial of PLB1003 by Beijing Pearl Biotechnology

As of April 19, 2017 lists a phase 1 trial of PLB1003 which targets ALK. At this time the trial is at one site: Shanghai Chest Hospital. To qualify you must have one measurable met in the body. The … Continue reading

Posted in Lung cancer, PLB1003 - Beijing Pearl Biotechnology, Potential Treatments, Research | Leave a comment